The global balloon occlusion market was valued at approximately $70 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 3.5%, reaching approximately $90 million by 2032.
This report covers the global market for balloon occlusion devices and includes complete market analyses of unit sales, average selling prices (ASPs), and market values. The report quantifies units sold, market size, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Balloon occlusion devices maintain a competitive position in the neurovascular market through a significant price advantage over stents for coiling procedures, making them the preferred option for cost-sensitive hospitals with capable staff. Technological advancements are also expanding the application range of balloon catheters beyond traditional uses, with recent evidence supporting their role in road-map imaging and flow-diverter placement.
The market faces meaningful structural headwinds. The widespread adoption of self-expanding neurovascular stents is reducing reliance on balloon-expandable alternatives, while declining use of liquid embolics for unruptured AVMs following the ARUBA trial findings has reduced demand for balloon occlusion catheters in one of their core procedural applications. These dynamics constrain growth despite the price-competitive positioning of balloon devices.
The primary commercial advantage of balloon occlusion devices is their price position relative to stents. For price-sensitive hospitals with appropriately trained staff, a balloon-assisted coiling approach is the preferred option due to the significantly lower per-procedure device cost compared to stent-assisted coiling. This cost differential, with balloon ASPs approximately five times lower than those of stents for comparable coiling indications, is expected to sustain demand for balloon devices among cost-conscious buyers throughout the forecast period.
Technological advancement is expanding the procedural versatility of balloon occlusion catheters. In addition to their established roles in coiling assistance and liquid embolic delivery, recent evidence has demonstrated that balloon catheters can be used as a tool to enable road-map imaging of parent vessels and to assist with flow-diverter placement. These emerging applications broaden the use cases for balloon devices and partially offset the volume pressure from structural market limiters.
Two structural headwinds are shaping the market's growth ceiling. First, the neurovascular stent market has moved predominantly toward self-expanding designs, which do not require balloon catheters for deployment and carry lower vessel trauma risk compared to balloon-expandable alternatives. Second, evolving clinical evidence on the management of unruptured arteriovenous malformations has reduced the role of liquid embolics, which in turn reduces the procedural demand for balloon occlusion catheters that are used alongside them.
Stryker was the second-leading competitor in the balloon occlusion device market in 2025. The company offers the Transform and Transform Super Occlusion Balloon catheters, which are single-lumen devices designed to control blood flow and support embolization procedures. Key product features include hydrophilic coating to reduce friction during navigation and radiopaque markers that improve visibility under fluoroscopy, supporting precise catheter positioning during procedures. Stryker's established presence across the broader neurovascular intervention market supports its distribution and clinical relationships in the balloon occlusion segment.
Medtronic was the third-leading competitor in the balloon occlusion device market in 2025. The company offers the HyperForm and HyperGlide occlusion balloon systems, originally developed through the Covidien acquisition. These devices are known for their adaptability to complex vessel anatomy and their ability to access distal vasculature, supporting use in anatomically demanding cases. Medtronic's combined neurovascular portfolio, which spans catheters, guidewires, and embolization platforms, allows it to position balloon occlusion products as part of a broader procedural offering.
4 charts and 8 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
This report covers the global market for balloon occlusion devices and includes complete market analyses of unit sales, average selling prices (ASPs), and market values. The report quantifies units sold, market size, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Balloon occlusion devices maintain a competitive position in the neurovascular market through a significant price advantage over stents for coiling procedures, making them the preferred option for cost-sensitive hospitals with capable staff. Technological advancements are also expanding the application range of balloon catheters beyond traditional uses, with recent evidence supporting their role in road-map imaging and flow-diverter placement.
The market faces meaningful structural headwinds. The widespread adoption of self-expanding neurovascular stents is reducing reliance on balloon-expandable alternatives, while declining use of liquid embolics for unruptured AVMs following the ARUBA trial findings has reduced demand for balloon occlusion catheters in one of their core procedural applications. These dynamics constrain growth despite the price-competitive positioning of balloon devices.
Market Overview
The global balloon occlusion market is a specialized segment within the broader neurovascular intervention space. Balloon occlusion catheters are used to temporarily block blood flow within a vessel during endovascular procedures, providing a controlled environment for embolization, device delivery, and imaging. They are used alongside liquid embolics to limit reflux of embolic material back into the artery, as well as in balloon-assisted coiling for wide-necked aneurysms where additional support is required to keep coils within the aneurysm sac. The market is small but serves a distinct procedural need within the neurovascular toolkit.The primary commercial advantage of balloon occlusion devices is their price position relative to stents. For price-sensitive hospitals with appropriately trained staff, a balloon-assisted coiling approach is the preferred option due to the significantly lower per-procedure device cost compared to stent-assisted coiling. This cost differential, with balloon ASPs approximately five times lower than those of stents for comparable coiling indications, is expected to sustain demand for balloon devices among cost-conscious buyers throughout the forecast period.
Technological advancement is expanding the procedural versatility of balloon occlusion catheters. In addition to their established roles in coiling assistance and liquid embolic delivery, recent evidence has demonstrated that balloon catheters can be used as a tool to enable road-map imaging of parent vessels and to assist with flow-diverter placement. These emerging applications broaden the use cases for balloon devices and partially offset the volume pressure from structural market limiters.
Two structural headwinds are shaping the market's growth ceiling. First, the neurovascular stent market has moved predominantly toward self-expanding designs, which do not require balloon catheters for deployment and carry lower vessel trauma risk compared to balloon-expandable alternatives. Second, evolving clinical evidence on the management of unruptured arteriovenous malformations has reduced the role of liquid embolics, which in turn reduces the procedural demand for balloon occlusion catheters that are used alongside them.
Market Drivers
Incentive Pricing
The ASP of balloon occlusion devices is approximately five times lower than the price of stents for coiling procedures, making them the preferred option for price-sensitive hospitals with the staff capability to perform balloon-assisted coiling. This substantial cost advantage allows balloon devices to remain competitive in the neurovascular market even as more advanced technologies become available. In healthcare environments where budget management is a priority and where the clinical outcome difference between balloon-assisted and stent-assisted coiling is not definitive for certain aneurysm types, the cost case for balloon occlusion is straightforward. This pricing dynamic is expected to sustain a reliable base of demand throughout the forecast period, particularly in emerging markets where cost sensitivity is more pronounced.Technological Advancement
Technological advancements are enabling novel uses for balloon occlusion devices that extend their clinical value beyond traditional procedural roles. A 2022 study demonstrated that balloon catheters can be used as a method to enable road-map imaging of parent vessels and to assist with flow-diverter placement, representing a meaningful expansion of their application. Ongoing improvements to balloon catheter design, including dual-lumen configurations that allow simultaneous balloon inflation and device delivery through a single catheter, are also making procedures more efficient and supporting adoption in complex cases. As stent and flow-diverter procedures grow in volume, the potential for balloon catheters to serve as adjunctive tools in these settings adds incremental demand to the market.Market Limiters
Rise of Self-Expandable Stents
The majority of neurovascular stents on the market are now designed to be self-expanding rather than deployed via a balloon microcatheter. Self-expanding stents gently open to the desired vessel diameter and carry a lower risk of dissection or vessel rupture compared to balloon-expandable stents that were evaluated in earlier clinical trials. Because self-expanding stents do not require a balloon for deployment, their widespread adoption has reduced the procedural need for balloon occlusion catheters in stent-assisted aneurysm treatment. This shift has directly constrained unit sales for balloon devices in one of their historically core indications and represents a structural headwind that is expected to persist over the forecast period.Decline of Liquid Embolics
Balloon occlusion catheters are used in liquid embolic procedures to limit the reflux of embolic fluid back into the parent artery, making the volume of liquid embolic procedures a key demand driver for balloon devices. A 2020 follow-up to the ARUBA trial re-concluded that medication was a superior treatment method for unruptured arteriovenous malformations compared to interventional approaches including liquid embolization. This finding has contributed to a reduction in liquid embolic procedure volumes for unruptured AVMs, which in turn reduces demand for the balloon occlusion catheters used alongside them. As the clinical preference for conservative management of unruptured AVMs continues, this remains a meaningful structural limiter on balloon occlusion market growth.Market Coverage and Data Scope
- Quantitative coverage: Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
- Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
- Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
- Data sources: Primary interviews with neurovascular device industry leaders and neurointerventional physicians, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
- Care settings: Hospitals and neurovascular intervention centers.
Markets Covered and Segmentation
The balloon occlusion market is analyzed as a unified segment, assessed by unit volume, ASP, and market value with historical and forecast data provided:
- Balloon Occlusion Devices
Competitive Analysis
Terumo led the balloon occlusion device market in 2025 through its Scepter C and Scepter XC dual-lumen occlusion balloon catheters. These devices are designed for versatile use across stent delivery, liquid embolic procedures, and balloon occlusion applications. The dual-lumen design allows physicians to simultaneously inflate the balloon and deliver a device or agent through the same catheter, improving procedural efficiency in complex cases. Terumo's strength in the guiding catheter segment of the broader neurovascular market also supports its commercial relationships and distribution access in this adjacent balloon catheter category.Stryker was the second-leading competitor in the balloon occlusion device market in 2025. The company offers the Transform and Transform Super Occlusion Balloon catheters, which are single-lumen devices designed to control blood flow and support embolization procedures. Key product features include hydrophilic coating to reduce friction during navigation and radiopaque markers that improve visibility under fluoroscopy, supporting precise catheter positioning during procedures. Stryker's established presence across the broader neurovascular intervention market supports its distribution and clinical relationships in the balloon occlusion segment.
Medtronic was the third-leading competitor in the balloon occlusion device market in 2025. The company offers the HyperForm and HyperGlide occlusion balloon systems, originally developed through the Covidien acquisition. These devices are known for their adaptability to complex vessel anatomy and their ability to access distal vasculature, supporting use in anatomically demanding cases. Medtronic's combined neurovascular portfolio, which spans catheters, guidewires, and embolization platforms, allows it to position balloon occlusion products as part of a broader procedural offering.
Technology and Practice Trends
- Dual-lumen catheter design: Dual-lumen balloon configurations allow simultaneous balloon inflation and device or agent delivery through a single catheter, improving efficiency and reducing the number of exchanges required in complex procedures.
- Road-map imaging applications: Clinical evidence published in 2022 supports the use of balloon catheters for road-map imaging of parent vessels, expanding their role in procedures beyond coiling and embolization.
- Flow-diverter placement support: Balloon catheters are demonstrating utility in assisting flow-diverter deployment, adding a newer adjunctive application that creates incremental demand as flow-diverter procedure volumes grow.
- Hydrophilic coatings and radiopaque markers: Improvements to surface coatings and fluoroscopic visibility features are improving navigational performance and reducing friction-related complications during catheter delivery.
- Self-expanding stent displacement: The shift toward self-expanding neurovascular stents is reducing balloon catheter use in stent-assisted procedures, reshaping where balloon devices remain most clinically relevant.
- AVM management evolution: Changing clinical guidance on unruptured AVM treatment is reducing liquid embolic procedural volumes, which directly affects balloon occlusion catheter demand in that indication.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.Deliverables
38 pages of detailed narrative analysis, tables, and figures.4 charts and 8 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
Why This Report
- Where are the remaining growth opportunities within the global balloon occlusion market as self-expanding stents and declining liquid embolic volumes constrain traditional demand through 2032?
- How does the price advantage of balloon occlusion devices over stents for coiling support their commercial position in cost-sensitive hospital environments?
- What emerging procedural applications, including road-map imaging and flow-diverter placement assistance, are expanding the clinical role of balloon catheters?
- How are dual-lumen versus single-lumen catheter designs differentiated in terms of procedural utility and market positioning?
- Which companies lead the market and how do their product platforms address different procedural requirements in balloon-assisted neurovascular intervention?
- What is the outlook for balloon occlusion demand in liquid embolic procedures following the ARUBA trial findings on unruptured AVM management?
- How is the shift toward self-expanding stents reshaping the procedural settings where balloon occlusion catheters remain most clinically relevant?
- What are the key risks to growth, including structural volume headwinds from stent technology evolution and changing AVM treatment guidelines?
Table of Contents
Research Methodology
Balloon Occlusion Market
List of Charts
List of Figures
